Results 1 to 10 of about 20,678 (258)
Renoprotective Effects of DPP-4 Inhibitors [PDF]
Antioxidants, 2021 Diabetic kidney disease (DKD) is the leading cause of end-stage renal disease (ESRD) worldwide. Dipeptidyl peptidase (DPP)-4 inhibitors are widely used in the treatment of patients with type 2 diabetes (T2D).
Yuichi Takashi +2 more
exaly +5 more sources
Clinical Use of DPP-4 Inhibitors [PDF]
Frontiers in Endocrinology, 2019 DPP-4 inhibitors were introduced for the treatment of type 2 diabetes in 2006. They stimulate insulin secretion and inhibit glucagon secretion by elevating endogenous GLP-1 concentrations without an intrinsic hypoglycaemia risk.
Baptist Gallwitz, Gallwitz Baptist
exaly +5 more sources
DPP-4 inhibitors for treating T2DM - hype or hope? an analysis based on the current literature
Frontiers in Molecular Biosciences, 2023 DPP-4 inhibition is an interesting line of therapy for treating Type 2 Diabetes Mellitus (T2DM) and is based on promoting the incretin effect. Here, the authors have presented a brief appraisal of DPP-4 inhibitors, their modes of action, and the clinical
Smriti Sharma
exaly +3 more sources
Target trial emulation of DPP-4 Inhibitors in patients with T2DM for pulmonary tuberculosis: a nationwide observational data [PDF]
BMC MedicineBackground Diabetes mellitus increases the risk of developing tuberculosis (TB) and negatively affects TB treatment outcomes. Dipeptidyl peptidase-4 (DPP-4) inhibitors are used in glycemic control but can also modulate immune pathways involved in immune ...
Yi-Geng Chen +8 more
doaj +2 more sources
Impact of DPP-4 Inhibitors in Patients with Diabetes Mellitus and Heart Failure: An In-Depth Review [PDF]
MedicinaThe increasing prevalence of both type 2 diabetes mellitus and heart failure has underscored the urgent need for optimized therapeutic strategies that address the complex interplay between these conditions.
Francisco Epelde
doaj +2 more sources
Emerging DPP-4 inhibitors: focus on linagliptin for type 2 diabetes
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2013 Baptist GallwitzDepartment of Medicine IV, Eberhard-Karls-University Tübingen, Tübingen, GermanyAbstract: The first dipeptidyl-peptidase-IV (DPP-4) inhibitor for the treatment of type 2 diabetes became available in 2006. Since then, the
Baptist Gallwitz
exaly +2 more sources
SAFETY PROFILE OF DIPEPTIDYL PEPTIDASE-4 INHIBITORS [PDF]
Trakia Journal of Sciences, 2023 Dipeptidyl peptidase-4 inhibitors (DPP-4 inhibitors) are oral antidiabetic agents commonly used for the treatment of type 2 diabetes mellitus. More than ten years of clinical experience with this group of drugs provides evidence of their efficacy and ...
M. Ganeva
doaj +1 more source
Frontiers in Public Health, 2021 Introduction: Dipeptidyl peptidase 4 inhibitors (DPP-4 inhibitors) are incretin-based oral antidiabetic drugs. Previous studies have shown an association between increased plasma activity of DPP-4 and chronic hepatitis C virus (HCV) infection. Dipeptidyl
Wei-Hao Hsu +13 more
doaj +1 more source
Therapeutic Advances in Drug Safety, 2022 Registration: PROSPERO: CRD42020210645 Introduction: We aimed to assess the safety of dipeptidyl peptidase-4 (DPP-4) inhibitors in older patients with type 2 diabetes with inadequate glycaemic control.
Katharina Doni +8 more
doaj +1 more source
Comparative Renal Effects of Dipeptidyl Peptidase-4 Inhibitors and Sodium-Glucose Cotransporter 2 Inhibitors on Individual Outcomes in Patients with Type 2 Diabetes: A Systematic Review and Network Meta-Analysis [PDF]
Endocrinology and Metabolism, 2021 Background To compare the renal effects of dipeptidyl peptidase-4 (DPP-4) inhibitors and sodium-glucose cotransporter 2 (SGLT2) inhibitors on individual outcomes in patients with type 2 diabetes. Methods We searched electronic databases (MEDLINE, Embase,
Jae Hyun Bae +5 more
doaj +1 more source